REFERENCES
1) Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Kaatsch P, Pastore G, Peris-Bonet R, Stiller CA. “Survival of European Children and Young Adults with Cancer Diagnosed 1995-2002.” European Journal of Cancer. 2009.
2) Diedrich KB, Fauser CJM, Devroey P. “Cancer and Fertility: Strategies to Preserve Fertility.” Reproductive Biomedicine Online 2011.
3) National Center for Health Statistics, Division of Vital Statistics, Center for Disease Control 1930-2004, public-use data file; 2005-2007.
4) Mullan F. “Seasons of survival: reflections of a f a physician with cancer.” N Engl J Med. 1985
5) Siegel R, Ma J, Zou Z, Jemal A. “Cancer statistics, 2014.” CA Cancer J Clin. 2014 6) Siegel R, Naishadham D, Jemal A. “Cancer statistics, 2012.” CA Cancer J Clin. 2012 7) DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, Alteri R, Robbins AS, Jemal A. “Cancer treatment and survivorship statistics, 2014.” CA Cancer J Clin.
2014
8) Howlader N, Noone AM, Krapcho M, et al, eds. SEER Cancer Statistics Review, 1975- 2008. Bethesda, MD: National Cancer Institute; 2011.
9) https://www.cancercare.on.ca/
10) Inskip PD, Curtis RE. “New malignancies following childhood cancer in the United States”. Int J Cancer. 2007.
11)Surveillance, Epidemiology, and End Results (SEER) Programm (www.seer.cancer.gov) SEER* Stat Database: Incidence-SEER 9 Regs Public-Use. Nov 2005 Sub (1973-2003), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer statistics Branch, released April 2006, based on November 2005 submission.
12) Stroud JS, Mutch S, Rader J, Powell M, Thaker P, Grisby PW. “Effect of cancer treatment on ovarian function”. Fert Steril, 2009
13) Levine J. “Gonadotoxicity of Cancer Therapies in Pediatric and Reproductive- Age Females.” Oncofertility Medical Practice: Clinical Issue and Implementation, 2012.
14) Wallace WH, Kelsey T. “Human ovarian reserve from conception to the menopause.”
PLoS One, 2010.
15) Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. “A Systematic Review of Tests Predicting Ovarian Reserve and IVF Outcome.” Human Reproduction Update 2006.
16) Durlinger AL, Visser JA, Themmen A. “Regulation of Ovarian Function: The Role of anti-Müllerian Hormone.” Reproduction (Cambridge, England) 2002.
17) Fong L, Laven JSE, Hakvoort-Cammel FGAJ, Schipper I, Visser JA, Themmen APN, De Jong FH, Van den Heuvel-Eibrink MM. “Assessment of Ovarian Reserve in Adult Childhood Cancer Survivors Using anti-Müllerian Hormone.” Human Reproduction 2009.
18) Rosendahl M, Andersen CY, La Cour Freiesleben N, Anders J, Løssl K, Andersen NA.
“Dynamics and Mechanisms of Chemotherapy-induced Ovarian Follicular Depletion in Women of Fertile Age.” Fertility and Sterility 2010.
19) Anderson RA, Themmen APN, Al Qahtani AM, Groome NP, Cameron DA. “The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer”. Human Reprod 2006.
20) Longhi A, Macchiagodena M, Vitali G, Bacci G. “Fertility in Male Patients Treated with Neoadjuvant Chemotherapy for Osteosarcoma.” Journal of Pediatric Hematology/oncology 2003.
21) Himelstein-Braw R, Peters H, Faber M. “Morphological Study of the Ovaries of Leukaemic Children.” British Journal of Cancer 1978.
22) Meirow D, Dor J, Kaufman B, Shrim A, Rabinovici J, Schiff E, Raanani H, Levron J, Fridman E.. “Cortical Fibrosis and Blood-vessels Damage in Human Ovaries Exposed to Chemotherapy. Potential Mechanisms of Ovarian Injury.” Human Reproduction 2007 23) Blumenfeld Z, Von Wolff M. “GnRH-analogues and Oral Contraceptives for Fertility Preservation in Women During Chemotherapy.” Human Reproduction Update. 2008.
24) Schilsky RL, et al. “Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin’s disease.” Am J Med. 1981.
25) Sanders JE, et al. “Pregnancies following high-dose cyclophosphamide with or without highdose busulfan or total-body irradiation and bone marrow transplantation.” Blood.
1996.
26) Wallace WH, Thomson AB, Kelsey TW. “ The radiosensitivity of the human oocyte”.
27).Critchley HO, Wallace WH, Shalet SM., “Abdominal radiation in childhood; the potential for pregnancy”. Br J Obstet Gynaecol 1992.
28) Wallace WH, et al. “Predicting age of ovarian failure after radiation to a fi eld that includes the ovaries.” Int J Radiat Oncol Biol Phys. 2005.
29) Donnez J, Bassil S. “Indications for Cryopreservation of Ovarian Tissue.” Human Reproduction Update 1998.
30) Bath LE, et al. “Hypothalamic-pituitary-ovarian dysfunction after prepubertal chemotherapy and cranial irradiation for acute leukaemia.” Hum Reprod. 2001.
31) Wallace WH, Shalet SM, Crowne EC, Morris-Jones PH, Gattamaneni HR. “Ovarian failure following abdominal irradiation in childhood: natural history and prognosis” Clin Oncol. 1989.
32) Barlow DH. “Premature ovarian failure.” Bailliere’s Clin Obstet Gynecol. 1996.
33) Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, Beck LN, Brennan LV, Oktay K. “American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2006.
34) Veeck LL, Bodine B, Clarke RN, Berrios R, Libraro J, Moschini RM, Zaninovic N, Rosenwaks Z. “High Pregnancy Rates Can Be Achieved after Freezing and Thawing Human Blastocysts.” Fertility and Sterility. 2004.
35) Wallace WH, Walker DA. “Conference Consensus Statement: Ethical and Research Dilemmas for Fertility Preservation in Children Treated for Cancer.” Hum Fertil. 2001.
36) Chen C. “Pregnancy after human oocyte cryopreservation.” Lancet 1986
37) The Practice Committees of the American Society for Reproductive Medicine and Society for Assisted Reproductive Technologies. “Mature Oocyte Cryopreservation: a Guideline.” Fertility and Sterility. 2013.
38) Rosendahl M, Timmermans Wielenga V, Nedergaard L , Kristensen SG, Ernst E, Rasmussen PE, Anderson M, Schmidt KT, Andersen CY. “Cryopreservation of Ovarian Tissue for Fertility Preservation: No Evidence of Malignant Cell Contamination in Ovarian Tissue from Patients with Breast Cancer.” Fertility and Sterility. 2011.
39) Tao T, Del Valle A. “Human oocyte and ovarian tissue cryopreservation and its application” . J assist Reprod Genet. 2008.
40) Cobo A, Bellver J, Domingo J, Perez S, Crespo J, Pellicer A, Remohi J. “New options in assisted reproduction technology: the Cryotop method of oocyte vitrification.” RBM Online. 2008.
41) Cao YX, Chian RC. “Fertility Preservation with Immature and in Vitro Matured Oocytes.” Seminars in Reproductive Medicine. 2009.
42) Von Wolff M, Montag M, Dittrich R, Denschlag D, Nawroth F, Lawrenz B. “Fertility Preservation in Women--a Practical Guide to Preservation Techniques and Therapeutic Strategies in Breast Cancer, Hodgkin’s Lymphoma and Borderline Ovarian Tumours by the Fertility Preservation Network FertiPROTEKT.” Archives of Gynecology and Obstetrics. 2011.
43)Donnez J, Dolmans MM. “Cryopreservation and Transplantation of Ovarian Tissue.”
Clinical Obstetrics and Gynecology. 2010.
44) Rodriguez-Wallberg KA, Oktay K. ”Options on fertility preservation in female cancer patients” Cancer Treatment Reviews. 2012.
45) Nomi M, Atala A, Coppi PD, et al. “Principals of neovascularization for tissue engineering”. Mol Aspects Med. 2002
46) Gründker C, Emons G. “Role of Gonadotropin-releasing Hormone (GnRH) in Ovarian Cancer.” Reproductive Biology and Endocrinology: RB&E. 2003.
47) Olive DL. “Gonatropin releasing hormone agonists for endometriosis.” N Engl J Med 2008
48) Pascale J, dolmans MM, Donnez J. “Fertility preservation in girls during childhood: is it feasible, efficient and safe and to whom should it be proposed?” Hum Reprod 2010 49) Dargent D Et al. “La trachelectomie elargie(te), une alternative a l’hysterectomie radicale dans le traitement des cancer infiltrants developpes sur la face externe du col uterin.“. 1994
50) Kesic V et al. “Fertility preserving management in gynaecologica cancer patients: the need for centralization”. Int J Gynecol Cancer. 2010.
51) West ER, Zelinski MB, Kondapalli LA, Gracia C, Chang J, Coutifaris C, Critser J, Stouffer RL, Shea LD, Woodruff T. “Preserving female fertility following cancer treatmetn: current options and future possibilities”. Pediatric Blood Cancer. 2011.
52) Speroff L, Fritz M. “Clinical gynecologic endocrinology and infertility.” Philadelphia:
Lippincott Williams & Wilkins; 2005.
53) Pal L, Leykin L, Schifren JL, Isaacson KB, Chang YC, Nikruil N, et al. “Malignancy may adversely influence the quality and behaviour of oocytes.” HumReprod 1998.
54) Friedler S, Koc O, Gidoni Y, Raziel A, Ron-El R. “Ovarian Response to Stimulation for Fertility Preservation in Women with Malignant Disease: a Systematic Review and Meta-analysis.” Fertility and Sterility. 2012.
55) Oktay K, Kim JY, Barad D, Babayev SN. “Association of BRCA1 Mutations with Occult Primary Ovarian Insufficiency: a Possible Explanation for the Link Between Infertility and Breast/ovarian Cancer Risks.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2010.
56) Lawrenz B, Fehm T, Von Wolff M, Soekler M, Huebner S, Henes J, Henes M, Centers of FertiPROTEKT Network. “Reduced Pretreatment Ovarian Reserve in Premenopausal Female Patients with Hodgkin Lymphoma or non-Hodgkin-lymphoma--evaluation by Using Antimüllerian Hormone and Retrieved Oocytes.” Fertility and Sterility. 2012.
57) McLaren JF, Wright Bates G. “Fertility Preservation in Women of Reproductive Age with Cancer.” American Journal of Obstetrics and Gynecology. 2012.
58) Anderson RA, Kinniburgh D, Baird DT. “Preliminary experience of the use of a gonadotrophin-releasing hormone antagonist in ovulation induction/invitro fertilization prior to cancer treatment.” Hum Reprod 1999.
59) Von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T. “Ovarian Stimulation to Cryopreserve Fertilized Oocytes in Cancer Patients Can Be Started in the Luteal Phase.” Fertility and Sterility.2009
60) Reddy J, Oktay K. “Ovarian Stimulation and Fertility Preservation with the Use of Aromatase Inhibitors in Women with Breast Cancer.” Fertility and Sterility. 2012
61) Steiner AZ, Terplan M, Paulson RJ. “Comparison of tamoxifen and clomiphene citrate
62) Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. “Fertility Preservation in Breast Cancer Patients: IVF and Embryo Cryopreservation after Ovarian Stimulation with Tamoxifen.” Human Reproduction. 2003.
63) Smith I.E, Dowsett M. “Aromatase Inhibitors in Breast Cancer.” The New England Journal of Medicine. 2003.
64) Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, Bang H. “Letrozole Reduces Estrogen and Gonadotropin Exposure in Women with Breast Cancer Undergoing Ovarian Stimulation before Chemotherapy.” The Journal of Clinical Endocrinology and Metabolism. 2006.
65) Azim A, Amr A, Costantini-Ferrando M, Oktay K. “Safety of Fertility Preservation by Ovarian Stimulation with Letrozole and Gonadotropins in Patients with Breast Cancer: a Prospective Controlled Study.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 2008.
66) Aurousseau MH, Samama MM, Belhassen A, Herve F, Hugues JN. “Risk of Thromboembolism in Relation to an In-vitro Fertilization Programme: Three Case Reports.” Human Reproduction. 1995.
67) Cakmak H, Rosen MP. “Ovarian Stimulation in Cancer Patients.” Fertility and Sterility. 2013.
68) Madrigrano A, Westphal L, Wapnir I. “Egg Retrieval with Cryopreservation Does Not Delay Breast Cancer Treatment.” American Journal of Surgery. 2007.
but Already Successful in Fertility Preservation.” European Journal of Cancer. 2009.
